Tyra Biosciences Quarterly Income Statement
NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.94-0.03 (-0.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tyra Biosciences revenue and earnings
Tyra Biosciences reported a net loss of $45.6 million, compared with a loss of $28.1 million a year earlier. Diluted earnings per share came in at -$0.69.
Summary generated from market data by MetaCap's automated system. Methodology
Tyra Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 49.00M | 42.00M | 36.52M | 32.94M | 31.45M | 31.85M | 29.74M | 28.60M | 23.53M | 22.32M | 25.63M | 23.96M |
| Research & Development | 39.20M | 33.47M | 28.19M | 25.47M | 24.31M | 24.96M | 22.18M | 22.70M | 18.00M | 17.20M | 20.68M | 19.27M |
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Operating Income | -49.00M | -42.00M | -36.52M | -32.94M | -31.45M | -31.85M | -29.74M | -28.60M | -23.53M | -22.32M | -25.63M | -23.96M |
| Other Income (Expense) | 3.44M | 2.69M | 2.68M | 3.08M | 3.35M | 3.70M | 4.17M | 4.59M | 4.83M | 4.13M | 2.80M | 2.81M |
| Net Income | -45.56M | -39.30M | -33.83M | -29.87M | -28.10M | -28.15M | -25.57M | -24.02M | -18.70M | -18.19M | -22.83M | -21.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 | -0.41 | -0.32 | -0.35 | -0.54 | -0.49 |
| EPS (Diluted) | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 | -0.41 | -0.32 | -0.35 | -0.54 | -0.49 |
| Shares Outstanding (Basic) | 65.99M | 61.75M | — | 59.67M | 59.55M | 59.34M | — | 58.87M | 58.67M | 52.23M | — | 42.87M |
| Shares Outstanding (Diluted) | 65.99M | 61.75M | — | 59.67M | 59.55M | 59.34M | — | 58.87M | 58.67M | 52.23M | — | 42.87M |
| EBITDA | -48.87M | -41.86M | -36.38M | -32.81M | -31.31M | -31.71M | -29.60M | -28.48M | -23.41M | -22.20M | -25.53M | -23.88M |
This table shows 12 quarterly periods of Tyra Biosciences's income statement, from Q2 2026 back to Q3 2023, across 11 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow TYRA's reporting calendar. What is a income statement?